These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 12814458)

  • 1. Comparison of the micro- and macro-vascular effects of glimepiride and gliclazide in metformin-treated patients with Type 2 diabetes: a double-blind, crossover study.
    Dhindsa P; Davis KR; Donnelly R
    Br J Clin Pharmacol; 2003 Jun; 55(6):616-9. PubMed ID: 12814458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular effects of glibenclamide vs. glimepiride and metformin in Type 2 diabetic patients.
    Abbink EJ; Pickkers P; Jansen van Rosendaal A; Lutterman JA; Tack CJ; Russel FG; Smits P
    Diabet Med; 2002 Feb; 19(2):136-43. PubMed ID: 11874430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
    Betteridge DJ; Vergès B
    Diabetologia; 2005 Dec; 48(12):2477-81. PubMed ID: 16283239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
    Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
    Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adding glimepiride to insulin+metformin in type 2 diabetes of more than 10 years' duration--a randomised, double-blind, placebo-controlled, cross-over study.
    Nybäck-Nakell Å; Adamson U; Lins PE; Landstedt-Hallin L
    Diabetes Res Clin Pract; 2014 Feb; 103(2):286-91. PubMed ID: 24485398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of glimepiride (HOE490) in NIDDM, including a double blind comparative study versus gliclazide.
    Tsumura K
    Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S147-9. PubMed ID: 8529507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effects of glibenclamide and metformin on ambulatory blood pressure and cardiovascular reactivity in NIDDM.
    Sundaresan P; Lykos D; Daher A; Diamond T; Morris R; Howes LG
    Diabetes Care; 1997 May; 20(5):692-7. PubMed ID: 9135928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing kidney outcomes in type 2 diabetes treated with different sulphonylureas in real-life clinical practice.
    Lee YH; Lee CJ; Lee HS; Choe EY; Lee BW; Ahn CW; Cha BS; Lee HC; Balkau B; Kang ES
    Diabetes Metab; 2015 Jun; 41(3):208-15. PubMed ID: 25687901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sulfonylurea treatment of type 2 diabetic patients does not reduce the vasodilator response to ischemia.
    Spallarossa P; Schiavo M; Rossettin P; Cordone S; Olivotti L; Cordera R; Brunelli C
    Diabetes Care; 2001 Apr; 24(4):738-42. PubMed ID: 11315840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Free radical scavenging activity of sulfonylureas: a clinical assessment of the effect of gliclazide.
    Jennings PE; Belch JJ
    Metabolism; 2000 Feb; 49(2 Suppl 1):23-6. PubMed ID: 10693916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Umpierrez G; Issa M; Vlajnic A
    Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial.
    Vaccaro O; Masulli M; Nicolucci A; Bonora E; Del Prato S; Maggioni AP; Rivellese AA; Squatrito S; Giorda CB; Sesti G; Mocarelli P; Lucisano G; Sacco M; Signorini S; Cappellini F; Perriello G; Babini AC; Lapolla A; Gregori G; Giordano C; Corsi L; Buzzetti R; Clemente G; Di Cianni G; Iannarelli R; Cordera R; La Macchia O; Zamboni C; Scaranna C; Boemi M; Iovine C; Lauro D; Leotta S; Dall'Aglio E; Cannarsa E; Tonutti L; Pugliese G; Bossi AC; Anichini R; Dotta F; Di Benedetto A; Citro G; Antenucci D; Ricci L; Giorgino F; Santini C; Gnasso A; De Cosmo S; Zavaroni D; Vedovato M; Consoli A; Calabrese M; di Bartolo P; Fornengo P; Riccardi G; ;
    Lancet Diabetes Endocrinol; 2017 Nov; 5(11):887-897. PubMed ID: 28917544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiazolidinedione addition reduces the serum retinol-binding protein 4 in type 2 diabetic patients treated with metformin and sulfonylurea.
    Lin KD; Chang YH; Wang CL; Yang YH; Hsiao PJ; Li TH; Shin SJ
    Transl Res; 2008 Jun; 151(6):309-14. PubMed ID: 18514142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of insulin analogs as an add-on to metformin on cutaneous microcirculation in type 2 diabetic patients.
    Fysekidis M; Cosson E; Takbou K; Sutton A; Charnaux N; Banu I; Vicaut E; Valensi P
    Microvasc Res; 2018 Mar; 116():6-14. PubMed ID: 28954218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoglycemia in Frail Elderly Patients With Type 2 Diabetes Mellitus Treated With Sulfonylurea.
    van Dijk P; Bouma A; Landman GW; Groenier KH; Bilo H; Kleefstra N; van Hateren KJ
    J Diabetes Sci Technol; 2017 Mar; 11(2):438-439. PubMed ID: 27625346
    [No Abstract]   [Full Text] [Related]  

  • 17. Forearm vascular reactivity is differentially influenced by gliclazide and glibenclamide in chronically treated type 2 diabetic patients.
    Wascher TC; Boes U
    Clin Physiol Funct Imaging; 2005 Jan; 25(1):40-6. PubMed ID: 15659079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
    Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S
    Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is gliclazide a sulfonylurea with difference? A review in 2016.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2016 Jun; 9(6):839-51. PubMed ID: 26924475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of treatment with metformin and gliclazide in patients with non-insulin-dependent diabetes.
    McAlpine LG; McAlpine CH; Waclawski ER; Storer AM; Kay JW; Frier BM
    Eur J Clin Pharmacol; 1988; 34(2):129-32. PubMed ID: 3289948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.